Cell Proliferation News and Research

RSS

Study demonstrates how DISC1 variants affect brain development

Significant progress has been made in understanding the genetic risk factors underlying psychiatric disease. Recent studies have identified common genetic mutations conferring modest risk and rare variants comprising significant risk. One example of a rare cause of psychiatric disorders is the Disrupted in Schizophrenia-1 (DISC1) gene, first identified in a large Scottish pedigree displaying schizophrenia, bipolar disorder and depression.

18 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

Researchers identify new cancer drug discovery approach

Researchers at the University of California, San Diego School of Medicine and the UC San Diego Moores Cancer Center have identified a new drug discovery approach enabling the destruction of the most highly proliferative tumors.

14 Nov 2011

Regulated gene transcription more complex than previously thought

Cells develop and thrive by turning genes on and off as needed in a precise pattern, a process known as regulated gene transcription. In a paper published in the Nov. 9 issue of the Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine say this process is even more complex than previously thought, with regulated genes actually relocated to other, more conducive places in the cell nucleus.

11 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011

Heidelberg scientists identify single protein responsible for varicose veins

Dr. Thomas Korff and his group at the Division of Cardiovascular Physiology of Heidelberg University's Institute of Physiology and Pathophysiology have now shown that the pathological remodeling processes causing varicose veins are mediated by a single protein.

5 Nov 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

Researchers shed light on inner workings of endocycle

An international team of researchers led by investigators in the U.S. and Germany has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth's biomass.

31 Oct 2011

Functional link between IKBKE and Akt activation in breast cancer

Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.

28 Oct 2011

Inhibition of protein kinase B suppresses IKBKE's oncogenic transformation

28 Oct 2011

Surgeons freeze organoid units and regenerate TESI for short bowel syndrome

Surgeons at Children's Hospital Los Angeles have conducted a study that could put regenerative tissue treatment for short bowel syndrome one step closer to the bedside. The researchers were able to successfully isolate and store organoid units and later generate tissue-engineered small intestine (TESI) in a mouse model. The groundbreaking results were presented at the 2011 Annual Clinical Congress of the American College of Surgeons.

27 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

Researchers identify cancer cell cycle-regulated mechanism

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have identified a cell cycle-regulated mechanism behind the transformation of normal cells into cancerous cells.

22 Oct 2011

Potential new protein target for pulmonary hypertension

A protein critical to development appears to have a grave impact on lungs exposed to smoking and air pollution, researchers report.

18 Oct 2011

New onset tenderness after combo hormone therapy increases risk of breast cancer

Post-menopausal women who experience new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to women who don't experience breast tenderness, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has shown.

15 Oct 2011

Researchers identify age-dependent beta cell proliferation pathway

As a person ages, the ability of their beta cells to divide and make new beta cells declines. By the time children reach the age of 10 to 12 years, the ability of their insulin-producing cells to replicate greatly diminishes. If these cells, called beta cells, are destroyed-as they are in type 1 diabetes-treatment with the hormone insulin becomes essential to regulate blood glucose levels and get energy from food.

13 Oct 2011

Intellikine commences INK1117 Phase I dose escalation study in cancer

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

12 Oct 2011